Drug Trial Radar · NCT00988039
Europe-Africa Research Network for Evaluation of Second-line Therapy
Last checked: Nov 19, 2026Latest source record: Apr 4, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,277
Actual
Start
Mar 2010
Primary completion
Jan 2014
Study completion Jan 2014
Sponsor
- Lead sponsor
- Justine BolesGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- European and Developing Countries Clinical Trials Partnership (EDCTP)
- First posted
- Oct 1, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial aim is to ascertain what, if anything, needs to be combined with a boosted protease inhibitor (bPI) backbone in second-line therapy in order to maximize the chance of a good clinical outcome following WHO-defined failure on a first-line nucleoside reverse transcriptase inhibitor (NRTI) and NNRTI-containing regimen with probable extensive NRTI and NNRTI resistance mutations.
Conditions
- Human Immunodeficiency Virus
- HIV
Interventions
Aluvia + 2NRTIsDrug
Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy.
Aluvia + raltegravirDrug
Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily raltegravir (400mg) twice daily
Aluvia monotherapyDrug
Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily raltegravir (400mg) twice daily for the first 12 weeks only
Primary outcomes
What the sponsor says the trial is designed to measure.
- Good HIV disease control defined as a composite endpoint consisting of all of: - No new WHO stage 4 events - CD4 count >250 cells/mm3 - viral load <10,000 copies/ml or >10,000 copies/ml with no PI resistance mutationsTime frame: week 96
Locations
14 sites in 5 countries. Site status is shown where the registry gives one.
AMPATH Centre at Moi Teaching Referral Hospital
Eldoret, Kenya
University of Malawi
Blantyre, Malawi
Mzuzu Central Hospital
Mzuzu, Malawi
Joint Clinical Research Centre
Fort Portal, Uganda
JCRC
Gulu, Uganda
JCRC
Kabale, Uganda
JCRC
Kakira, Uganda
Infectious Diseases Institute
Kampala, Uganda
Joint Clinical Research Centre
Kampala, Uganda
San Raphael of St Francis Hospital Nsambya
Kampala, Uganda
Joint Clinical Research Centre
Mbale, Uganda
Joint Clinical Research Centre
Mbarara, Uganda
University Teaching Hospital
Lusaka, Zambia
University of Zimbabwe Clinical Research Centre
Harare, Zimbabwe
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.